Advances in human cardiac 31P-MR spectroscopy: SLOOP and clinical applications
✍ Scribed by Markus von Kienlin; Meinrad Beer; Andreas Greiser; Dietbert Hahn; Kerstin Harre; Herbert Köstler; Wilfried Landschütz; Thomas Pabst; Jörn Sandstede; Stefan Neubauer
- Publisher
- John Wiley and Sons
- Year
- 2001
- Tongue
- English
- Weight
- 84 KB
- Volume
- 13
- Category
- Article
- ISSN
- 1053-1807
No coin nor oath required. For personal study only.
✦ Synopsis
Abstract
Phosphorus magnetic resonance spectroscopy (^31^P‐MRS) has revealed a lot about the biochemistry of physiological and pathological processes in the heart. Nevertheless, until today, cardiac ^31^P‐MRS has not had any clinical impact, albeit some pioneering studies demonstrated that ^31^P‐MRS can indeed provide diagnostic information. In this paper, the development of techniques for human cardiac ^31^P‐MRS over the past decade is reviewed, and the requirements for a reliable clinical measurement protocol are discussed. Spatial localization with optimal pointspread function (SLOOP) is a new method to achieve spatial localization and absolute quantitation. Its properties are detailed, and preliminary findings in patients with dilated cardiomyopathy or myocardial infarction are presented. J. Magn. Reson. Imaging 2001;13:521–527. © 2001 Wiley‐Liss, Inc.
📜 SIMILAR VOLUMES
## Abstract The aim of this study was to apply ^31^P magnetic resonance spectroscopy (MRS) using spatial localization with optimal point spread function (SLOOP) to investigate possible age and gender dependencies of the energy metabolite concentrations in the human heart. Thirty healthy volunteers
Several pioneering studies have demonstrated that localized 31 P NMR spectroscopy of the human heart might become an important diagnostic tool in cardiology. The main limitation is due to the low sensitivity of these experiments, allowing only crude spatial resolution. We have implemented a three-di
## Abstract Proton‐decoupled phosphorus‐31 heart spectros‐copy was performed in healthy subjects (n = 9) and patients with dilated cardiomyopathy (DCM, n = 9) or hypertrophic cardiomyopathy (HCM, n = 8). The phosphocreatine (PCr)‐to–adenosine triphosphate ratio (± one standard deviation) after corr